- Gain exposure to advanced genomic sequencing for pennies on the dollar.
- Acacia has a stake in a company with arguably the most advanced class of DNA sequencing currently under development.
- Three private investments, Immunocore, AMO Pharma and Viamet, are booked at a combined $31m on Acacia’s balance sheet, while their true market value may exceed $277m.
- Acacia may be worth north of $15/share and most of this additional value is easily identifiable, nearly certain, highly liquid with upcoming catalysts to unlock it.
For further details see:
Acacia Research: Next Generation Genomic Sequencing At A Bargain Price